Guggenheim Rates Nuvalent (NUVL) hold, $124 Price Target
Guggenheim lowers its rating on Nuvalent Inc to hold, setting a $124.00 price target as shares trade near the top of their 52-week range, a 0.61% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Guggenheim rated Nuvalent Inc ($NUVL) "hold" with a $124 price target on June 10, 2026.
Since the rating, $NUVL is up 0.0% after 1 week and up 0.1% to date (from the $123.35 close on Jun 10, 2026).
NUVL
Nuvalent Inc
Key Points
- Guggenheim lowered its rating on Nuvalent Inc (NGM:NUVL) to a hold on June 10, 2026, setting a target price of $124.00.
- Guggenheim's $124 price target implies 0.61% upside from Nuvalent Inc's ($NUVL) current $123.25 share price.
- Shares trade near $123.25, sitting close to the 52-week high of $123.99 and well above the 52-week low of $71.13.
- The broader analyst group maintains a consensus hold rating across 9 analyst opinions, pointing to a mean price target of $124.00.
Get $NUVL trade alerts by text
We text you when insiders, Congress or big funds trade $NUVL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nuvalent Inc alert may contain errors. Disclosures
Guggenheim Lowers Nuvalent Inc NGM:NUVL to Hold Rating
Guggenheim lowered its rating on Nuvalent Inc (NGM:NUVL) to a hold on June 10, 2026, setting a target price of $124.00. Analyst Brad Canino pointed to a reassessment of the clinical-stage biotech firm's valuation following recent equity gains. The adjustment reflects a measured view on how much upside remains as the stock trades close to the newly minted price target.
Stock Performance and Valuation Gap
Shares changed hands around $123.25, pressing tightly against the 52-week high of $123.99 and well clear of the 52-week low of $71.13. That spot price sits nearly equal to Guggenheim's $124.00 target, leaving very little room between current market value and the firm's expectations. The equity continues to ride high above its 50-day moving average of $114.66 and its 200-day moving average of $105.26. Because Nuvalent is a pre-profit clinical-stage company reporting negative earnings per share, it carries no meaningful P/E ratio.
$NUVL price target
Nuvalent Inc daily closes and this analyst's $124 target. Not advice.
Wider Analyst Shifts on Nuvalent Inc NGM:NUVL
Other research houses have also tuned their outlooks for the biotechnology developer. On June 24, 2026, Bernstein adjusted its stance by downgrading the stock to a market perform rating while trimming its target to $124.00 from a prior target of $172.00. Across the street, the consensus recommendation rests at a hold backed by 9 analyst opinions with a mean price target of $124.00.
Inside Nuvalent Inc NGM:NUVL Operations
Headquartered in Cambridge, Massachusetts, Nuvalent focuses on creating targeted medicines for cancer patients facing treatment resistance and brain metastases. Its pipeline features candidates like Zidesamtinib for ROS1-positive non-small cell lung cancer, Neladalkib for ALK-positive tumors, and NVL-330 designed for HER2-driven cancers. These programs aim to sidestep adverse events that often limit older generations of kinase inhibitors.
What Lies Ahead for Nuvalent Inc NGM:NUVL
Market watchers will follow upcoming trial updates and corporate announcements for clues on how the lead drug candidates advance through clinical testing. Investors should keep in mind that analyst ratings and price targets can shift quickly as new trial data emerges from the company's ongoing studies.
Related Filing Alerts
Source: Guggenheim's rating change on $NUVL (Jun 10, 2026). Written by software, not financial advice. How we make alerts